Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 2
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type"
Page 1
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Kraft RM, et al. Hematol Oncol. 2021 Dec;39(5):658-663. doi: 10.1002/hon.2919. Epub 2021 Aug 28. Hematol Oncol. 2021. PMID: 34453851
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a rare, aggressive lymphoma characterized by skin involvement predominantly in the lower extremities. ...R-CHOP with ISRT had a signifi …
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is a …
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.
Ducharme O, Beylot-Barry M, Pham-Ledard A, Bohers E, Viailly PJ, Bandres T, Faur N, Frison E, Vergier B, Jardin F, Merlio JP, Gros A. Ducharme O, et al. J Invest Dermatol. 2019 Nov;139(11):2334-2342.e8. doi: 10.1016/j.jid.2019.05.008. Epub 2019 May 29. J Invest Dermatol. 2019. PMID: 31150604 Free article.
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) preferentially involves the lower limb in elderly subjects. ...The mutational profile of PCLBCL-LT has highlighted mutations contributing to consti …
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) prefere …
Primary cutaneous marginal zone lymphoma presenting with secondary chilblains of the toes.
Nasir AZ, Burmeister RS. Nasir AZ, et al. BMJ Case Rep. 2023 Aug 27;16(8):e255894. doi: 10.1136/bcr-2023-255894. BMJ Case Rep. 2023. PMID: 37640411
Cutaneous lymphoproliferative disorders include cutaneous manifestations of systemic B-cell or T-cell lymphoma and primary cutaneous lymphomas. Primary cutaneous B-cell lymphomas are subcategorised into …
Cutaneous lymphoproliferative disorders include cutaneous manifestations of systemic B-cell or T-cell lymphom …
Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, Puccini B, Fimiani M, Bosi A, Bocchia M, Pimpinelli N; Gruppo Italiano Linfomi Cutanei (GILC). Fabbri A, et al. Eur J Haematol. 2014 Aug;93(2):129-36. doi: 10.1111/ejh.12315. Epub 2014 Apr 4. Eur J Haematol. 2014. PMID: 24635751
BACKGROUND: In primary cutaneous B-cell lymphomas (PCBCL), radiotherapy - or surgery in a minority of cases - is the first-line treatment in follicle center lymphoma (PCFCL) and marginal zone B-cell lymphoma (PCMZL). Convers …
BACKGROUND: In primary cutaneous B-cell lymphomas (PCBCL), radiotherapy - or surgery in a minority of cases - is …
Can cutaneous low-grade B-cell lymphoma transform into primary cutaneous diffuse large B-cell lymphoma? An immunohistochemical study of 82 cases.
Plaza JA, Kacerovska D, Sangueza M, Schieke S, Buonaccorsi N, Suster S, Kazakov DV. Plaza JA, et al. Am J Dermatopathol. 2014 Jun;36(6):478-82. doi: 10.1097/DAD.0000000000000009. Am J Dermatopathol. 2014. PMID: 24698933
The risk of transformation of a cutaneous low-grade B-cell lymphoma, such as primary cutaneous follicle center cell lymphoma, to primary cutaneous diffuse large B-cell lymphomas (PCDLBCL) h …
The risk of transformation of a cutaneous low-grade B-cell lymphoma, such as primary cutaneous fol …
Efficacy and safety of pegylated liposomal doxorubicin in primary cutaneous B-cell lymphomas and comparison with the commonly used therapies.
Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Bettacchi A, Mulattieri S, Picardi P, Tassetti A, Scortechini AR, Fioritoni G, Leoni P. Pulini S, et al. Eur J Haematol. 2009 Mar;82(3):184-93. doi: 10.1111/j.1600-0609.2008.01197.x. Eur J Haematol. 2009. PMID: 19215609 Clinical Trial.
OBJECTIVES: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent data indicate a favourable pharmacokynetic, pharmacodynamic and toxicity profile of pegylated liposomal doxorubicin (Peg-Doxo) in primar …
OBJECTIVES: The therapy of advanced, relapsed or refractory primary cutaneous lymphomas is often unsatisfactory. Recent …